|
"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to avapro hct 2 diabetes.". N Engl J Med 345 (12): 851-60. PMID 11565517.^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian avapro hct Handbook; 2006. ISBN 0-9757919-2-3.
hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.Contents [hide]1 Clinical use1.1 Indications1.2 Combination with diuretic2 References3 See also[edit] avapro hct useMain article: Angiotensin II receptor avapro hct irbesartan is indicated for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under avapro hct trade names to avapro hct preparations, avapro hct CoAprovel, Karvezide, Avalide avapro hct Avapro HCT.[edit] References^ Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; avapro hct Study Group. (2001). "Renoprotective effect of the avapro hct antagonist irbesartan in patients with nephropathy due to type 2 diabetes.". N Engl J Med 345 (12): 851-60. PMID 11565517.^ Rossi S, editor. Australian.
RC, Rohde R, Raz I; Collaborative Study Group. (2001). "Renoprotective effect of the.
| 
Comments
It is very necessary!
__________________
http://shop-med.org pharma shop